Deal round-up 06/03/02

US biotechnology company Agensys raises $43m from international venture capital firms.

Privately-held US biotechnology firm Agensys has announced the successful completion of a $43m financing round. Proceeds from the financing will be used to generate therapeutic human antibodies to treat several different types of solid tumour cancers and advance them into clinical development.

Four European venture capital funds HBM, Lombard Odies, Carnegie and BSI joined a syndicate of ten institutional investors in the private placing. JP Morgan H&Q acted as placement agent and financial advisor for the offering. Bear Stearns investing through its Health Innoventures (BSHI) was the lead investor, with Orbimed Advisors and Alta Partners as co-leads.